Literature DB >> 11783701

European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori.

Y Glupczynski1, F Mégraud, M Lopez-Brea, L P Andersen.   

Abstract

A multicentre in vitro survey was carried out in 1998 in 22 European centres in order to assess the variation in the prevalence of Helicobacter pylori resistance. The susceptibility of 1,274 isolates to metronidazole, clarithromycin and amoxicillin was determined by the E test. The mean rate of resistance to metronidazole was 33.1% (95% CI, 7.5-58.9), to clarithromycin 9.9% (95% CI, 0-28.1) and to amoxicillin 0.8% (95% CI, 0-8.9). Resistance to metronidazole was significantly higher in females (P<0.001), while resistance to clarithromycin was significantly higher in children and teens (P<0.05). Resistance to both agents also tended to be higher in strains isolated from patients from southern European countries than in those isolated from patients from central or northern Europe. Overall, these results emphasize the need for further surveys of Helicobacter pylori sensitivity to antibiotics at a national and regional level.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11783701     DOI: 10.1007/s100960100611

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  75 in total

1.  Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection.

Authors:  Ala I Sharara; Fayez S Sarkis; Mustapha M El-Halabi; Ahmad Malli; Nabil M Mansour; Cecilio Azar; Mohamad A Eloubeidi; Fadi H Mourad; Kassem Barada; Ismail Sukkarieh
Journal:  United European Gastroenterol J       Date:  2014-06       Impact factor: 4.623

Review 2.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

3.  Prevalence of Helicobacter pylori in symptomatic patients and detection of clarithromycin resistance using melting curve analysis.

Authors:  Ayse Demet Kaya; C Elif Oztürk; Yusuf Akcan; Mustafa Behçet; A Esra Karakoç; Mihriban Yücel; Müge Mısırlıoglu; Serdar Tuncer
Journal:  Curr Ther Res Clin Exp       Date:  2007-05

4.  Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone.

Authors:  Yi-Chia Lee; Jyh-Ming Liou; Ming-Shiang Wu; Chun-Ying Wu; Jaw-Town Lin
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

5.  Helicobacter pylori and antibiotic resistance.

Authors:  Francis Megraud
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

6.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

7.  Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA.

Authors:  Jason Y Park; Kerry B Dunbar; Midori Mitui; Christina A Arnold; Dora M Lam-Himlin; Mark A Valasek; Irene Thung; Chinemerem Okwara; Elizabeth Coss; Byron Cryer; Christopher D Doern
Journal:  Dig Dis Sci       Date:  2016-02-29       Impact factor: 3.199

Review 8.  Diagnostic methods for Helicobacter pylori detection and eradication.

Authors:  A F Goddard; R P H Logan
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

9.  In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori.

Authors:  Morris O Makobongo; Tchelet Kovachi; Hanan Gancz; Amram Mor; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

Review 10.  How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?

Authors:  Enzo Ierardi; Floriana Giorgio; Giuseppe Losurdo; Alfredo Di Leo; Mariabeatrice Principi
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.